As such, we estimated the efficacy and safety of atezolizumab plus chemotherapy versus atezolizumab alone for the first-line treatment of advanced NSCLC patients in a PD-L1 TC3/IC3 subgroup through an indirect comparison meta-analysis. This evidence concerns the gene CD274 and non-small cell lung carcinoma.